ReForm Biologics Announces the Issuance of U.S. and Japanese Patents for Therapeutic Protein Formulations

WOBURN, Mass.--(BUSINESS WIRE)--ReForm Biologics, a pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, expanded its patent portfolio with the issuance of U.S. Patent No. 10,610,600 and its first patent in Japan, Japanese Patent No. 6674910.

The U.S. patent, entitled “Stabilizing Excipients for Therapeutic Protein Formulations,” provides ReForm exclusive rights to therapeutic protein formulations that include a new class of stabilizers that significantly reduce protein aggregation and stabilize proteins during storage. These stabilizers offer a promising alternative to conventional surfactants. With ReForm’s stable surfactant replacements for polysorbates in biologic formulations, biopharmaceutical companies may reduce protein aggregation and ultimately improve patient care.

The Japanese patent, entitled “Viscosity-Reducing Excipient Compounds for Protein Formulations,” covers formulations containing an excipient that significantly reduces the viscosity of highly concentrated therapeutic antibody solutions. ReForm believes that viscosity reduction will allow for more effective formulation and preferable routes of delivering such antibody solutions to patients.

“ReForm continues to build its portfolio of intellectual property for its innovative formulation platform. The U.S. patent provides ReForm with exclusive rights for the use of its stabilizer excipient for a broad range of therapeutic proteins, while the Japanese patent allows for the use of our viscosity reduction technology in Japan,” said John M. Sorvillo, PhD, Chief Executive Officer. “These new patents are a cornerstone of our proprietary technology platforms to improve biologic formulations.”

ReForm has recently announced a licensing agreement with MilliporeSigma, the Life Science business of Merck KGaA, Darmstadt, Germany to commercialize proprietary ReForm excipients used in biotherapeutic formulations. ReForm previously announced individual agreements with Astellas Pharma Inc., Bayer AG, and KBI Biopharma, Inc. to enhance the formulations of biologics based on ReForm’s patented technology.

About ReForm Biologics

ReForm Biologics has developed a technology platform that transforms the formulation of biotherapeutics for the ultimate benefit of patients. Our patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for our biopharmaceutical partners. With multiple industry alliances to date, we offer formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics.

We don’t make biologics — we make biologics better. www.reformbiologics.com